Colorectal Cancer | Current Treatment: Physician Insights | US | 2019
Market Outlook
Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting. The FDA approvals of the PD-1 inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb) in 2017 and of Opdivo plus Yervoy in 2018 for microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) metastatic colorectal cancer herald the entry of immunotherapy treatments to this biomarker-defined patient population.
Questions Answered
- What is the uptake of Keytruda and Opdivo in the previously treated MSI-H/dMMR metastatic colorectal cancer segment in the United States, and what are the main obstacles to prescribing these immunotherapies?
- What is the patient share of key therapies used to treat RASwild-type and RAS-mutant metastatic colorectal cancer?
- What drivers and obstacles influence treatment decisions in the metastatic setting for select targeted therapies?
- How do drug-treatment rates vary between key colorectal cancer patient segments, according to biomarker status and line of therapy?
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States
Primary Research: Survey of 100 medical oncologists in the United States
Key Drugs Covered: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, Opdivo, Zaltrap, Cyramza, Stivarga, Yervoy
